Amgen Inc. $AMGN Stake Lessened by TIAA Trust National Association

TIAA Trust National Association cut its stake in Amgen Inc. (NASDAQ:AMGN) by 3.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,350 shares of the medical research company’s stock after selling 1,502 shares during the period. TIAA Trust National Association’s holdings in Amgen were worth $13,862,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. lifted its stake in Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after purchasing an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC acquired a new stake in Amgen during the fourth quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. lifted its stake in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after purchasing an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Amgen during the fourth quarter valued at approximately $22,441,000. Finally, Sigma Planning Corp lifted its stake in Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock valued at $5,889,000 after purchasing an additional 3,488 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by insiders.

Amgen Stock Down 0.3%

Shares of NASDAQ:AMGN opened at $344.57 on Wednesday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market cap of $185.97 billion, a PE ratio of 23.98, a price-to-earnings-growth ratio of 3.47 and a beta of 0.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The firm has a 50 day simple moving average of $341.12 and a 200 day simple moving average of $345.52.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts expect that Amgen Inc. will post 22.38 earnings per share for the current year.

Analysts Set New Price Targets

AMGN has been the subject of several recent research reports. Morgan Stanley set a $340.00 target price on shares of Amgen in a research note on Tuesday. Piper Sandler cut their target price on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Royal Bank Of Canada increased their target price on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Mizuho increased their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $354.12.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.